Kangmei Pharma | 600518 - Equity Capital And Reserves


Kangmei Pharma reported CNY7.31B in Equity Capital and Reserves for its fiscal quarter ending in March of 2026.





Equity Capital And Reserves Change Date
Akebia Therapeutics USD 27.38M 5.24M Mar/2026
Alaunos Therapeutics USD 1.29M 865K Mar/2026
Avita Medical AUD -16.65M 3.76M Dec/2025
Cspc Pharmaceutical CNY 33.18B 71.46M Dec/2025
Dianthus Therapeutics USD 1.2B 707.91M Mar/2026
Genomma Lab Internacional MXN 11.72B 603.74M Mar/2026
Hypermarcas BRL 14.12B 1.6B Mar/2026
Ionis Pharmaceuticals USD 491.41M 2.32M Mar/2026
IQVIA Holdings USD 6.22B 282M Mar/2026
Jiangsu Hengrui CNY 63.63B 2.35B Mar/2026
Kangmei Pharma CNY 7.31B 84.82M Mar/2026
Moderna USD 7.41B 1.24B Mar/2026
Organon & Co USD 903M 151M Mar/2026
Revvity USD 7.25B 125.54M Dec/2025
Sh Fosun Pharma CNY 49.15B 248.15M Mar/2026
Tectonic Therapeutic USD 230.42M 20.91M Mar/2026
Viatris USD 14.66B 53.6M Mar/2026
Wuxi Apptec CNY 84.77B 4.11B Mar/2026
Xeris Pharmaceuticals USD 13.01M 678K Mar/2026
Zz Pientze Pharmaceu CNY 15.21B 740.32M Mar/2026